Business
Skin Cancer Imaging with MoleMate(tm) Accelerates New Revenue Growth Strategy Via Entry Into Multiple Hundred Million Dollar Markets and On-Line Services
Expanded discussion at the Annual Shareholders' Meeting Scheduled for March 13, 2012, 4 ...
About this update from Medx Health Corp.
[{"type":"text","content":"\n\n\n\n\n\nExpanded discussion at the Annual Shareholders' Meeting Scheduled for March 13, 2012, 4 p.m. in Toronto at The National Club\n\n\nMISSISSAUGA, ON, March 5, 2012 /CNW/ - MedX Health Corp., (TSXV: MDX) a global leader in drug free, non-invasive low level laser light therapy\n and light imaging systems, announced today that the Annual\n Shareholders' Meeting will be held on March 13, 2012, at 4 p.m. at the\n National Club in Toronto, where the President and CEO, Steve Guillen\n will review how MoleMate has accelerated the transition into new\n markets, including on-line services.\n\n\nAt the upcoming meeting of shareholders, Mr. Guillen will expand and\n update upon the following regarding MoleMate:\n\n\nTransition to a technology platform company;\n\n\nOn-line imaging services utilizing 'cloud' technology;\n\n\nAcceleration of new market entries: skin cancer, burns, wound care;\n\n\nAddition of Mole Mapping in 2012;\n\n\nBroad worldwide patent portfolio;\n\n\nStrong sales in Q4 2011, led by MoleMate; best quarter in over three (3)\n years;\n\n\nImmediate availability in Canada, the US, and other locations around the\n world.\n\n\n\"We are fundamentally changing from simply a medical device company to a\n technology platform company, with broad worldwide patents, and\n positioned to enter multiple hundred million dollar markets where\n knowing what is just under the skin is critical for the quality of care\n of the patient,\" says Steve Guillen, President and CEO, and \"by\n offering a web based solution, via 'cloud' technology, we can lower the\n initial cost to physicians, as physicians pay monthly service fees,\n creating an on-going revenue stream for MedX from each device sold.\"\n\n\nSkin Cancer Imaging - First Target\n\n\nThe combined markets in Europe, Canada, Australia, and the US is worth\n over $200 Million in net device sales (Zach's Equity Research), and the\n opportunity via 'cloud' technology for recurring revenue could be worth\n millions of dollars every year in this emerging market.\n\n\nBurns Assessment Imaging, Diabetic Foot Ulcer Imaging - Second Target\n\n\nThe worldwide advanced wound care market (burns, diabetic foot ulcers\n and bed sores) is estimated at $5 Billion (Global Industry Analysts,\n Inc.) and the market potential using the MedX platform technology may\n be worth hundreds of millions ...